Strides Pharma Science Limited has informed the Exchange that Board of Directors at its meeting held on May 22, 2025, recommended Final Dividend of Rs. 4 per equity share.
STAR · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.7 pts more than Nifty Microcap 250 and 5.7 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Strides Pharma Science Limited's Board of Directors, at their meeting on May 22, 2025, approved audited financial results (standalone and consolidated) for Q4 and the financial year ended March 31, 2025. The Board recommended a final dividend of Rs. 4 per equity share of Rs. 10 each, at a rate of 40%, which will be paid within 30 days of shareholder approval at the upcoming AGM. Statutory auditors B S R & Co. LLP issued an unmodified opinion on both the standalone and consolidated results. The figures reflect the impact of the NCLT-approved Scheme of Arrangement for the demerger of the company's CDMO and Soft Gelatin business, which was given effect from the retrospective appointed date of April 1, 2024.
Eligible shareholders will receive a Rs. 4 per share dividend once the AGM approves it, subject to a record date to be announced. The clean audit opinion and post-demerger clarity may support investor confidence, though prior-year results have been restated, which could affect year-on-year comparisons.